News & Articles

New service reduces project time from months to weeks for biopharma customers

Explore topics from live-cell analysis, in situ hybridization, cancer therapeutics, cell imaging, and much more

For a chance to win a $500/£400/450€ Amazon Gift Card, cast your vote for the new products which have made the most difference to clinical diagnostics

KSQ Therapeutics uses technology created at MIT to study the role of every human gene in disease biology

Dr. David Andrews, AstraZeneca, discusses the future of small-molecule drug discovery for PPIs

Amanda Kulwicki, Global Brand Manager at Thermo Fisher Scientific, discusses how her team ensures sample integrity with confidence

This study offers new insights into high grade serous ovarian cancer that have the potential to make an impact in how patients are treated in the future

Explore our exclusive interviews and free resources to help support your cancer research, diagnostics, and therapy development

Join thousands of scientists from around the world as they come together online to discuss the hottest topics and latest technology solutions

With this partnership, Repositive is expanding its personalized medicine capabilities to support more biopharma customers

The partnership will pair Personalis’ NeXT tumor profiling with Natera’s Signatera™ for treatment monitoring

Catch up on part one of our exclusive webinar series to hear Dr. Frank Peacock dispel the four lies of high-sensitivity troponin

Increasing Portuguese market presence by enhancing sales and after-sales support networks

Join us on Friday, February 26, to find out how to effectively profile the host response to COVID-19 infection using the next-generation automated ELISA, Ella

Find out how to overcome the challenges involved with establishing reference intervals for clinical interpretation in this on-demand webinar

New partnership broadens access to oncology treatments across Latin America, Asia, Africa and the Western Pacific

The integrated solution offers deeper insight into therapy resistance and relapse, saving billions in drug development costs